meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
6
mUC - L1 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
durvalumab based treatment
durvalumab alone
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
Gender, female
Gender, male
Hemoglobin concentration < 10g/dl
hemoglobin concentration > 10g/dl
metastasis (liver )
metastasis (lymph node )
metastasis (visceral)
smoker (Current)
smoker (Former)
smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
mUC - L1 - PDL1 positive
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - PDL1 positive
versus gemcitabine plus platin
durvalumab alone vs. gemcitabine plus platin
1
certainty unassessable
-10%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open